+

WO1999002190A1 - Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique - Google Patents

Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique Download PDF

Info

Publication number
WO1999002190A1
WO1999002190A1 PCT/US1997/012109 US9712109W WO9902190A1 WO 1999002190 A1 WO1999002190 A1 WO 1999002190A1 US 9712109 W US9712109 W US 9712109W WO 9902190 A1 WO9902190 A1 WO 9902190A1
Authority
WO
WIPO (PCT)
Prior art keywords
amphiphiles
amphiphile
cationic
cells
carbamate
Prior art date
Application number
PCT/US1997/012109
Other languages
English (en)
Inventor
Ronald K. Scheule
Rebecca G. Bagley
Simon J. Eastman
Seng H. Cheng
John Marshall
David J. Harris
Edward R. Lee
Craig S. Siegel
Chau-Dung Chang
C. Shirley Hubbard
Duane E. Johnson
Daniel C. Maneval
H. Michael Shepard
Richard J. Gregory
Original Assignee
Genzyme Corporation
Canji, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation, Canji, Inc. filed Critical Genzyme Corporation
Priority to PCT/US1997/012109 priority Critical patent/WO1999002190A1/fr
Priority to AU36594/97A priority patent/AU3659497A/en
Publication of WO1999002190A1 publication Critical patent/WO1999002190A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to novel cationic amphiphilic compounds that facilitate the intracellular delivery of biologically active (therapeutic) molecules.
  • the present invention relates also to pharmaceutical compositions that comprise such cationic amphiphiles, and that are useful to deliver into the cells of patients therapeutically effective amounts of biologically active molecules.
  • the novel cationic amphiphilic compounds of the invention are particularly useful in relation to gene therapy.
  • biologically active molecules for which effective targeting to a patients' tissues is often not achieved: (1) numerous proteins including immunoglobin proteins, (2) polynucleotides such as genomic DNA, cDNA, or mRNA (3) antisense polynucleotides; and (4) many low molecular weight compounds, whether synthetic or naturally occurring, such as the peptide hormones and antibiotics.
  • numerous proteins including immunoglobin proteins (2) polynucleotides such as genomic DNA, cDNA, or mRNA (3) antisense polynucleotides; and (4) many low molecular weight compounds, whether synthetic or naturally occurring, such as the peptide hormones and antibiotics.
  • One of the fundamental challenges now facing medical practicioners is that although the defective genes that are associated with numerous inherited diseases (or that represent disease risk factors including for various cancers) have been isolated and characterized, methods to correct the disease states themselves by providing patients with normal copies of such genes (the technique of gene therapy) are substantially lacking. Accordingly, the development of improved methods of intracellular delivery therefor is of great medical
  • diseases that it is hoped can be treated by gene therapy include inherited disorders such as cystic fibrosis, Gaucher's disease, Fabry's disease, and muscular dystrophy.
  • inherited disorders such as cystic fibrosis, Gaucher's disease, Fabry's disease, and muscular dystrophy.
  • acquired disorders that can be treated are: (1) for cancers — multiple myeloma, leukemias, melanomas, ovarian carcinoma and small cell lung cancer; (2) for cardiovascular conditions — progressive heart failure, restenosis, and hemophilias; and (3) for neurological conditions — traumatic brain injury.
  • Transfection requires successful transfection of target cells in a patient.
  • Transfection may generally be defined as the process of introducing an expressible polynucleotide (for example a gene, a cDNA, or an mRNA patterned thereon) into a cell.
  • an expressible polynucleotide for example a gene, a cDNA, or an mRNA patterned thereon
  • Successful expression of the encoding polynucleotide leads to production in the cells of a normal protein and leads to correction of the disease state associated with the abnormal gene.
  • Therapies based on providing such proteins directly to target cells are often ineffective for the reasons mentioned above.
  • Cystic fibrosis a common lethal genetic disorder, is a particular example of a disease that is a target for gene therapy.
  • the disease is caused by the presence of one or more mutations in the gene that encodes a protein known as cystic fibrosis transmembrane conductance regulator ("CFTR"), and which regulates the movement of ions (and therefore fluid) across the cell membrane of epithelial cells, including lung epithelial cells.
  • CTR cystic fibrosis transmembrane conductance regulator
  • Abnormnal ion transport in airway cells leads to abnormal mucous secretion, inflammmation and infection, tisssue damage, and eventually death.
  • amphiphiles Compounds having both such domains may be termed amphiphiles, and many lipids and synthetic lipids that have been disclosed for use in facilitating such intracellular delivery (whether for in vitro or in vivo application) meet this definition.
  • amphiphiles One particularly important class of such amphiphiles is the cationic amphiphiles.
  • cationic amphiphiles have polar groups that are capable of being positively charged at or around physiological pH, and this property is understood in the art to be important in defining how the amphiphiles interact with the many types of biologically active (therapeutic) molecules including, for example, negatively charged polynucleotides such as DNA.
  • cationic amphiphilic compounds that have both polar and non-polar domains and that are stated to be useful in relation to intracellular delivery of biologically active molecules are found, for example, in the following references, which contain also useful discussion of (1) the properties of such compounds that are understood in the art as making them suitable for such applications, and (2) the nature of structures, as understood in the art, that are formed by complexing of such amphiphiles with therapeutic molecules intended for intracellular delivery.
  • Feigner et al., Proc. Natl. Acad. Sci. USA. 84, 7413-7417 (1987) disclose use of positively-charged synthetic cationic lipids including N-[l(2,3- dioleyloxy)propyl]-N,N,N-trimethylammoniiim chloride ("DOTMA"), to form lipid/DNA complexes suitable for transfections.
  • DOTMA N-[l(2,3- dioleyloxy)propyl]-N,N,N-trimethylammoniiim chloride
  • This invention provides for cationic amphiphiles that are particularly effective to facilitate transport of biologically active molecules into cells.
  • the cationic amphiphiles of the invention are divided into four (4) groups, although it will be seen that there are certain structural and functional features that many of the amphiphiles share.
  • amphiphiles of Group I capable of facilitating transport of biologically active molecules into cells, said amphiphiles having the structure (I),
  • Z is a steroid
  • X is a carbon atom or a nitrogen atom
  • Y is a short linking group , or Y is absent;
  • R3 is H, or a saturated or unsaturated aliphatic group
  • R is — NH- , an alkylamine, or a polyalkylamine;
  • R4 is H, or a saturated or unsaturated aliphatic group;
  • R2 is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R ⁇ , except that both Rl and R ⁇ cannot be — NH— .
  • the steroid component "Z" is selected from the group consisting of 3-sterols, wherein said sterol molecule is linked by the 3- O- group thereof , or by N- in replacement thereof, to Y (or directly to X, if Y is absent ).
  • particularly effective amphiphiles include, for example, spermidine cholesterol carbamate ( N ⁇
  • the steroid group is linked to Y (or directly to X, if Y is absent) from ring position 17 of the steroid nucleus (see Figures 1 and 22), or from the arm that normally extends from position 17 in many steroids( see the structure of cholesterol in Figure 1), or from any shortened form of said arm.
  • linking group Y are contained no more than about three or four atoms that themselves form a bridge of covalent bonds between X and Z.
  • Y is a linking group wherein no more than one atom of said group forms a bond with both X and Z, or Y is absent.
  • amphiphiles provided according to Group I include:
  • amphiphiles of Group LI capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (LI),
  • Z is a steroid
  • X is a carbon atom or a nitrogen atom
  • Y is a linking group or Y is absent
  • R3 is an amino acid, a derivatized amino acid, H or alkyl;
  • Rl is — NH— , an alkylamine, or a polyalkylamine;
  • R4 is an amino acid, a derivatized amino acid, H or alkyl
  • R is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R ⁇ , except that both Rl and R ⁇ cannot be — NH— .
  • Representative amphiphiles provided according to Group LI include:
  • amphiphiles of Group m capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (IE),
  • Z is an alkylamine or a dialkylamine, linked by the N-atom thereof, to Y ( or directly to X, if Y is absent ), wherein if Z is a dialkylamine, the alkyl groups thereof can be the same or different;
  • X is a carbon atom or a nitrogen atom;
  • Y is a short linking group , or Y is absent;
  • R3 is H, or a saturated or unsaturated aliphatic group
  • Rl is — NH— , an alkylamine, or a polyalkylamine
  • R4 is H, or a saturated or unsaturated aliphatic group
  • R2 is — NH— , an alkylamine, or a polyalkylarnine; and wherein Rl is the same or is different from R ⁇ , except that both Rl and R2 cannot be — NH— .
  • linking group Y there are contained no more than about three or four atoms that themselves form a bridge of covalent bonds between X and Z.
  • amphiphiles provided according to Group LLI include:
  • N,N-dioctadecyllysineamide diHCl salt triaminohexane tri HC1 salt Additionally there are provided cationic amphiphiles of Group IV (see Figure 7) capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (IV),
  • a and B are independently O, N or S;
  • R D and R" are independently alkyl or acyl groups and may be saturated or contain sites of unsaturation;
  • E is a carbon atom or a nitrogen atom
  • R3 is H, or a saturated or unsaturated aliphatic group
  • Rl is — NH— , an alkylamine, or a polyalkylamine
  • R4 is H, or a saturated or unsaturated aliphatic group
  • R2 is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R ⁇ , except that both Rl and R2 cannot be — NH— .
  • compositions that comprise one or more cationic amphiphiles, and one or more biologically active molecules, wherein said compositions facilitate intracellular delivery in the tissues of patients of therapeutically effective amounts of the biologically active molecules.
  • the pharmaceutical compositions of the invention may be formulated to contain one or more additional physiologically acceptable substances that stabilize the compositions for storage and /or contribute to the successful intracellular delivery of the biologically active molecules.
  • the invention provides a method for facilitating the transfer of biologically active molecules into cells comprising the steps of: preparing a dispersion of a cationic amphiphile of the invention; contacting said dispersion with a biologically active molecule to form a complex between said amphiphile and said molecule, and contacting cells with said complex thereby facilitating transfer of said biologically-active molecule into the cells.
  • the cationic amphiphile(s) of the invention may be formulated with one or more additional cationic amphiphiles including those known in the art, or with neutral co-lipids such as dioleoylphosphatidyl- ethanolamine, (" DOPE"), to facilitate delivery to cells of the biologically active molecules.
  • compositions that comprise one or more cationic amphiphiles of the invention can be used to introduce biologically active molecules into plant cells, such as plant cells in tissue culture.
  • the present application provides for novel plasmids suitable for complexing with the amphiphiles of the invention in order to treat patients by gene therapy, so that a high level of expression of the appropriate therapeutic transgene can be achieved.
  • Representative examples thereof include the lasmid pCMVHI and pCFI.
  • pCFl plasmid contains the enhancer /promoter region from the immediate early gene of cytomegalovirus.
  • the plamid also contains a hybrid intron located between the promoter and the transgene cDNA.
  • the polyadenylation signal of the bovine growth hormone gene was selected for placement downstream from the transgene.
  • plasmid performance is made possible by the provision of replicating episomal plasmids.
  • Additional therapeutic enhancements are made possible by providing plasmids in which expression of the therapeutic transgene is placed under the control of a transcriptional promoter that is sensitive to the concentration of inflammation-related substances in the target tissue.
  • Such plasmids are of particular use for the treatment of clinical cases in which inflammation is a major complication.
  • particular organs or tissues may be targeted for gene therapy, by intravenous administration of amphiphile/transgene complexes, by adjusting the ratio of amphiphile to DNA in such complexes, and by adjusting the apparent charge or zeta potential thereof.
  • FIGUREl depicts representative Group I cationic amphophiles.
  • FIGURE 2 depicts representative steroid lipophilic groups.
  • FIGURE 3 depicts representative steroid lipophilic groups.
  • FIGURE 4 depicts a transacylation reaction.
  • FIGURE 5 depicts represenative Group LT cationic amphiphiles.
  • FIGURE 6 depicts represenative Group HI cationic amphiphiles.
  • FIGURE 7 depicts representative Group IV cationic amphiphiles.
  • FIGURE 8 provides a route of synthesis for spermidine cholesterol carbamate.
  • FIGURE 9 provides a route of synthesis for spe ⁇ r ⁇ ne cholesterol carbamate
  • FIGURE 10 provides a comparison of in vivo transfection efficiency for certain cationic amphiphiles under particular conditions.
  • FIGURE 11 is a depiction of in vivo transfection effeciency as a function of DNA concentration for a particular cationic amphiphile.
  • FIGURE 12 is a depiction of in vivo transfection effeciency as a function of concentration of a particular cationic amphiphile.
  • FIGURE 13 provides relative transfection efficiencies for Group I amphiphiles.
  • FIGURE 14 provides relative transfection efficiencies for Group 13 amphiphiles.
  • FIGURE 15 provides relative transfection efficiencies for Group IV amphiphiles.
  • FIGURE 16 provides a map of pCMVHI-CAT plasmid.
  • FIGURE 17 shows the hybrid intron of pCMVHI-CAT.
  • FIGURE 18 (panel A) provides a map of pCFl/CAT plasmid.
  • FIGURE 18 panel B provides a map of pCF2/CAT plasmid.
  • FIGURE 19 panel A shows a plot of corrected chloride ion transport in pCMV-CFTR transfected nasal polyp epithelial cells from a cystic fibrosis patient.
  • FIGURE 19 (panel B) shows a plot of chloride ion transport using pCMV- ⁇ - galactosidase control.
  • FIGURE 20 provides a map of pMyc4-CFTR plasmid.
  • FIGURE 21 demonstrates intravenous targeting of the heart and lung.
  • FIGURE 22 demonstrates expression of SEAP following intravenous administration in BALB/c mice.
  • FIGURE 23 is a map for pCTM-Rb plasmid.
  • FIGURE 24 is a survival curve from a mouse model following administration of human tumor cells, and a DNA encoding the human retinoblastoma protein.
  • This invention provides for cationic amphiphile compounds, and compositions containing them, that are useful to facilitate transport of biologically active molecules into cells.
  • the amphiphiles are particularly useful in facilitating the transport of biologically active polynucleotides into cells, and in particular to the cells of patients for the purpose of gene therapy.
  • Cationic amphiphiles possess several novel features. These features may be seen in comparison with, for example, cationic amphiphile structures such as those disclosed in U.S. Patent No. 5, 283,185 to Epand et al., a representative structure of which is is is 3fi [N- (N 1,N1 - dirne ylarninoethane)-carbamoyl] cholesterol, commonly known as "DC-chol”, and to those disclosed by Behr et al. Proc. Natl. Acad. Sci.. USA.86, 6982- 6986 (1989), a representative structure of which is dioctadecylamidolo- glycylspermine ("DOGS").
  • DOGS dioctadecylamidolo- glycylspermine
  • Cationic amphiphiles of the present invention contain distinctive structural features: (1) the presence of a lipophilic group which is connected directly, or through a linking group, to two cationic groups (see below) that themselves comprise amino, alkylamine or polyalkylamine groups, there resulting an overall and novel "T-shaped" structure; and (2) in many cases, and in comparison with numerous art-recognized amphiphiles, the use of a relatively short linking group to bring into close proximity the lipophilic and cationic regions of the amphiphile. Without being limited as to theory, it is believed that these features contribute substantially to the transfection-enhancing capability of these compounds.
  • Figure 10 below demonstrates the very substantial in vivo transfection-enhancing capability of spermidine cholesterol carbamate (a novel amphiphile of the invention) in comparision to DC- chol and DMRLE — two well recognized transfectants.
  • cationic means that the R groups, as defined herein, tend to have one or more positive charges in a solution that is at or near physiological pH. Such cationic character may enhance interaction of the amphiphile with therapeutic molecules (such as nucleic acids) or with cell structures (such as plasma membrane glycoproteins) thereby contributing to successful entry of the therapeutic molecules into cells, or processing within subcompartments (such as the nucleus) thereof.
  • therapeutic molecules such as nucleic acids
  • cell structures such as plasma membrane glycoproteins
  • Bio molecules for which transport into cells can be facilitated according to the practice of the invention include, for example, genomic DNA, cDNA, mRNA, antisense RNA or DNA, polypeptides and small molecular weight drugs or hormones. Representative examples thereof are mentioned below in connection with the description of therapeutic (pharmaceutical) compositions of the invention.
  • the biologically active molecule is an encoding polynucleotide that is expressed when placed in the cells of a patient leading to the correction of a metabolic defect.
  • the polynucleotide encodes for a polypeptide having an amino acid sequence sufficiently duplicative of that of human cystic fibrosis transmembrane regulator ("CFTR") to allow possession of the biological property of epithelial cell anion channel regulation.
  • CFTR human cystic fibrosis transmembrane regulator
  • characteristic and novel features of the amphiphiles of the invention include first, that the linking group that connects the two cationic amine groups to the lipophilic group is very short, or absent entirely, and second, that the resultant linking of the the two cationic R groups to the lipophilic group forms a T-shaped structure when viewed from the position of atom "X" (a carbon or nitrogen atom) as depicted, for example, in Structures (I), (LI), (HI) and (IV, see atom "E").
  • atom "X" a carbon or nitrogen atom
  • both spermidine cholesterol carbamate ( N ⁇ -spermidine cholesteryl carbamate) and spermine cholesterol carbamate ( N ⁇ -spermine cholesteryl carbamate) have been determinedto be superior transfectants in vivo in comparison with non "T- shaped" amphiphiles having otherwise equivalent amounts of cationic alkylamine structure.
  • Superior performance (see also Example 3) has been determined for:
  • amphiphiles 53, 67, 78, 90, and 91 are representative.
  • the placement of the nitrogen atoms in the polar head groups of the amphiphiles such that they are separated by one or more combinations of 3 and 4 carbon atoms leads to high in vivo transfection efficiency for plasmid transgenes complexed therewith.
  • amphiphiles of Group I capable of facilitating transport of biologically active molecules into cells, said amphiphiles having the structure (I),
  • Z is a steroid
  • X is a carbon atom or a nitrogen atom;
  • Y is a short linking group , or Y is absent;
  • R3 is H, or a saturated or unsaturated aliphatic group
  • Rl is — NH— , an alkylamine, or a polyalkylamine
  • R4 is H, or a saturated or unsaturated aliphatic group
  • R2 is -NH- , an alkylamine, or a polyalkylamine
  • Rl is the same or is different from R ⁇ , except that both Rl and R ⁇ cannot be — NH— .
  • the Linking Group Preferably the linking group that connects the lipophilic group to the two cationic R groups is relatively short. It is preferred that within linking group Y are contained no more than about three or four atoms that themselves form a bridge of covalent bonds between X and Z.
  • Additional linking g ⁇ oups useful in the practice of the invention are those patterned on small amino acids such as glycinyl, alanyl, beta-alanyl, serinyl, and the like.
  • Y is a linking group wherein no more than one atom of this group forms a bond with both "X"and "Z".
  • the linking group "Y” may be absent entirely.
  • "X” forms a connecting point in the amphiphiles to which is also attached the two cationic R groups. As can be seen therein (see also Figure 1), the placement of the nitrogen atom that represents "X” clearly causes the molecule to assume a T-shape.
  • Steroid Lipophilic Groups Cationic amphiphiles according to the practice of the invention may include a variety of structures as lipophilic group.
  • Steroids represent a preferred group of such structures. With respect to the design and orientation of steroids as lipophilic groups according to the practice of the invention, the following considerations are of note. Steroids are widely distributed in the animal, microbial and plant kingdoms. They may be defined as solid alcohols that typically contain, as their basic skeleton, 17 carbon atoms arranged in the form of a perhydrocyclopenteno- phenanthrene ring system. Accordingly, such compounds include bile acids, cholesterol and related substances, vitamin D, certain insect molting hormones, certain sex hormones, corticoid hormones, certain antibiotics, and derivatives of all of the above wherein additional rings are added or are deleted from the basic structure, [see Natural Products Chemistry, K.
  • steroid is used broadly to include related molecules derived from multiple isoprenoid units, such as vitamin E. Steroids representative of those useful in the practice of the invention are shown in Figures 1, 2, 3 and 5.
  • certain preferred amphiphiles of the invention include a steroid component "Z" that is selected from the group consisting of 3- sterols, wherein said sterol molecule is linked by the 3-O- group thereof , or by N- in replacement thereof, to Y (see Figure 1).
  • Such structures include, for example, spermidine cholesterol carbamate, spermine cholesterol carbamate, spermidine 7-dehydrocholesteryl carbamate, lysine 3-N-dihydrocholesteryl carbamate, spermidine cholestamine urea, and N-3-aminopropyl-N ⁇ 4- aminobutylcholestamine.
  • the steroid group is linked to Y (or directly to X if Y is absent) from ring position 17 of the steroid nucleus (see Figures 1 and 3), or from the arm that normally extends from position 17 in many steroids (see Figures 1 and 3), or from any shortened form of said arm.
  • the molecules have structures which can be metabolized by the body and are nontoxic at the doses thereof that are used.
  • steroids such as cholesterol and ergosterol that are substantially non toxic and which possess biologically normal stereospecificity in order to facilitate their safe metabolism in patients.
  • Additional steroids useful in the practice of the invention include, for example, ergosterol BI, ergosterol B2, ergosterol B3, androsterone, cholic acid, desoxycholic acid, chenodesoxycholic acid, lithocholic acid and, for example, various derivatives thereof as are shown in the panels of Figures 2 and 3.
  • any ring position or substituent on the steroid can in general be used as point of attachment. It is preferred, however, to use a point of attachment that (1) mimimizes the complexity of chemical syntheses, and (2) is positioned near either "end" of the steroid molecule, for example , a position near ring position 3, or near ring position 17( or the arm that typically extends therefrom).
  • Such positions provide an orientation of the steroid with respect to the rest of the amphiphile structure that faciliates bilayer formation, and /or micelle formation, and /or stabilizes interaction with the biologically active molecules to be carried into the target cells.
  • Representative structures showing attachment of the cationic (alkyl) amine groups to the steroid lipophilic group through the arm extending from ring position 17 therof are shown in Figure 3 (panels A, B).
  • any polar groups on the steroid such as may be attached to ring position 3, be either removed or capped (for example, hydroxy as methoxy) to avoid potentially destabilizing bilayer or micelle structures.
  • Preferred steroids for use as group "Z" according to the practice of the invention include: 3- sterols (derived from cholesterol)
  • Representative species of steroid that are patterened on ergosterol and that may be used to define the structure of cationic amphiphiles of the invention include: ergosterol (double bonds as shown); ergosterol BI ( ⁇ 8, 9; ⁇ 14, 15; ⁇ 22, 23); ergosterol BI ( ⁇ 6, 7; ⁇ 8, 14; ⁇ 22, 23); ergosterol BI ( ⁇ 7, 8; ⁇ 14, 15; ⁇ 22, 23); and lumisterol ( the 9b-H isomer of ergosterol).
  • R 3 and R 4 are, independently, H, or saturated or unsaturated aliphatic groups.
  • the aliphatic groups can be branched or unbranched. Representative groups include alkyl, alkenyl, and cycloalkyl.
  • Rl and R 2 are, independently, H, or saturated or unsaturated aliphatic groups.
  • the aliphatic groups can be branched or unbranched. Representative groups include alkyl, alkenyl, and cycloalkyl.
  • Rl and R 2 represent structures recognized in the art as being amine; alkylamines (including primary, secondary, and tertiary amines), or extended versions thereof-herein termed "polyalkylamines". It is understood that both alkylamine and polyalkylamine groups as defined herein may include one or more carbon-carbon double bonds and the use of such alkenylamines is therefore within the practice of the invention.
  • Representative alkylamines include: (a) — NH-(CH2)z — where z is other than 0; (b) - [[CH3(CH2)y)N] -(CH2) Z - where z is other than 0; and (c) - [[CH3(CH2) ⁇ ][CH3(CH2)y]]N -(CH2)z - where z is other than 0.
  • Rl and R 2 are tertiary amines, such as is represented in Structure (c) above, it is understood that a hydrogen atom corresponding to either R 3 or R 4 , as appropriate, may or may not be present since such hydrogen atoms correspond to the N:H(+) structure whose level of protonation will vary according to pH.
  • polyalkylamine as referred to herein defines a polymeric structure in which at least two alkylamines are joined.
  • the alkylamine units that are so joined may be primary or secondary, and the polyalkylamines that result may contain primary, secondary, or tertiary N-atoms.
  • the alkylamine (sub)units may be saturated or unsaturated, and therefore the term “alkylamine” encompasses alkenylamines in the description of the invention.
  • Representative resultant polyalkylamines include: (d) — [NH-(CH2)(z)]q - , where z is other than 0, and q is 2 or higher; (e) - [NH-(CH2) (y) ]p - [NH- (CH2)(z)]q — where y and z are each other than 0, and p and q are each other than 0; (f) - [NH-(CH 2 )( ⁇ )]n -[NH-(CH 2 ) (y) ]p - [NH-(CH 2 )(z)]q - , where x, y, and z are each other than 0, and n, p and q are each other than 0; (g) — [NH- (CH 2 )(w)]m - [NH-(CH 2 )( ⁇ )]n -[NH-(CH 2 )(y)]p - [NH-(CH 2 )(z)]q - , where
  • Rl and R 2 independently, can be — NH- , an alkylamine, or a polyalkylamine, and can be the same or different from each other, except that both Rl and R 2 cannot be — NH— in order to (1) preserve the "T- shape" of the resultant compound, and (2) to provide for the stability thereof. It is preferred that - in combination- the combined backbone length of R3R! (or of R 4 R2) be less than about 40 atoms of nitrogen and carbon, more preferrably less than about 30 atoms of nitrogen and carbon.
  • Rl group adjacent to R 3 includes a terminal nitrogen atom that defines a tertiary center
  • Rl group adjacent to R 3 includes a terminal nitrogen atom that defines a tertiary center
  • a quaternary amine is formed (at that nitrogen atom of Rl) if R 3 is an aliphatic group, and a tertiary amine remains (at that nitrogen atom of R ) if R 3 is H.
  • R 3 Rl— (or R 4 R2— ) structures to atom "X" is through the right hand side (as depicted) of the R 3 R — , that is, through a CH2 — moiety.
  • the coefficents i.e. v, w, x, y, and z and 1, m, n, p, and q
  • v, w, x, y, and z and 1, m, n, p, and q represent whole numbers.
  • whole number means 0 and the natural numbers 1,2,3,4,5,6 and up, unless specifically restricted.
  • a polyalkylamine may be represented, for example, by the formulas above, although many more structures (such structures being within the scope of the invention) can be depicted by extending the number of, or types or combinations of, alkylamine subunits within the amphiphile structure. That further such variations can be made is apparent to those skilled in the art.
  • a polyalkylamine group (or resultant R 3 R1 group) that is very long may interfere, for example, with the solubility of the resultant amphiphile, or interfere with its ability to stably interact with the biologically active molecule selected for intracellular delivery.
  • polyalkylamines (or resultant R 3 Rl groups) having a backbone length of about 40 nitrogen and carbon atoms, or more may not be suitable for inclusion in amphiphiles.
  • its properties may be determined by experimentation, and its use is nonetheless within the practice of the invention.
  • amphiphiles of Group LI capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (LI),
  • Z is a steroid
  • X is a carbon atom or a nitrogen atom
  • Y is a linking group or Y is absent
  • R 3 is an amino acid, a derivatized amino acid, H or alkyl
  • Rl is — NH— , an alkylamine, or a polyalkylamine
  • R 4 is an amino acid, a derivatized amino acid, H or alkyl;
  • R2 is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R 2 , except that both R and R 2 cannot be — NH— .
  • amphiphiles provided according to Group II include amphiphiles 87, 91, 93, 95, 97, 99, 100, and 103. With respect to the structural features of these amphiphiles, and the other amphiphiles of Group LI, the following should be considered.
  • the steroid group may be selected according to the criteria defined above for the Group I amphiphiles. Accordingly, preferred amphiphiles include those selected from 3- sterols, wherein the sterol molecule is linked by the 3-O- group thereof, or by N in replacement thereof, to "Y".
  • group Y may be absent.
  • Representative N-acylamino groups include an N-Acyl serine ( No. 87), an N-Acyl glycine (No. 91), and an N- Acyl aspartic acid ( No. 103). With respect to the use of N-Acyl aspartic acid in amphiphile No. 103, it is noted that, as provided, the gamma carboxyl thereof is further derivatized to an additional alkylamine moiety.
  • R 3 and R 4 represent H or alkyl, or may be natural or artificial amino acids including derivatives of either.
  • Representative examples of R 3 or R 4 amino acid groups include those derived from tryptophan ( No. 97) and from arginine ( No. 95).
  • amphiphiles of Group HI capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (HI),
  • Z is an alkylamine or a dialkylamine, linked by the N-atom thereof, to Y, or directly to X if Y is absent, wherein if Z is a dialkylamine, the alkyl groups thereof can be the same or different;
  • X is a carbon atom or a nitrogen atom
  • Y is a short linking group , or Y is absent;
  • R 3 is H, or a saturated or unsaturated aliphatic group
  • Rl is — NH— , an alkylamine, or a polyalkylamine;
  • R 4 is H, or a saturated or unsaturated aliphatic group;
  • R2 is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R 2 , except that both Rl and R 2 cannot be — NH— .
  • Representative cationic amphiphiles according to the practice of the mvention that contain an alkyl amine or dialkylamine as lipophilic group include, for example, N,N-dioctadecyllysineamide; N , Nl-dioctadecyl-1,2,6- triaminohexane; N,N-didodecyllysineamide; N,N- didecyllysineamide; spermidine- N,N- dioctadecyl urea; N-myristyllysineamide; and N- (dioctyldecylaminoethyl)-lysineamide .
  • Representative amphiphiles are depicted
  • an alkyl chain(s) of the group should not be so large in molecular weight that it interferes with the solubility of the amphiphile, or interferes with its ability to interact with plasmid DNA.
  • an alkyl chain of an alkylamine or dialkylamine may include one or more points of unsaturation.
  • Group I amphiphiles and these R groups may be selected, for example, from Table I.
  • Group IV Amphiphiles
  • amphiphiles of Group IN capable of facilitating transport of biologically active molecules into cells said amphiphiles having the structure (LV),
  • a and B are independently O, N or S;
  • R D and R ⁇ are independently alkyl or acyl groups and may be saturated or contain sites of unsaturation;
  • E (analogous to "X" in structures I, LI, LU) is a carbon atom or a nitrogen atom;
  • R 3 is H, or a saturated or unsaturated aliphatic group;
  • Rl is — NH— , an alkylamine, or a polyalkylamine
  • R 4 is H, or a saturated or unsaturated aliphatic group
  • R 2 is — NH— , an alkylamine, or a polyalkylamine; and wherein Rl is the same or is different from R 2 , except that both Rl and R 2 cannot be -NH-.
  • Representative amphiphiles of Group IN include ⁇ os. 64, 76, 85, 89, 94, 98,
  • group "E” represents a carbon atom or a nitrogen atom.
  • R5 and R ⁇ are independently alkyl or acyl groups, preferrably containing about 8 to about 30 carbon atoms, and such groups may contain one or more points of unsaturation.
  • group D may be absent (amphiphile No.94). Additional linkers may be selected based on the teachings provided with respect to Groups I, H, and HI above, and based upon the in vivo test date derived ( Figure 15), it is preferred that the linker D be short or absent.
  • DOPE dioleoylphosphatidylethanolamine
  • diphytanoylphosphatidyl- ethanolamine lyso-phosphatidylethanolamines other phosphatidyl- ethanolamines
  • phosphatidylcholines lyso-phosphatidylcholines and cholesterol.
  • a preferred molar ratio of cationic amphiphile to colipid is about 1:1.
  • amphiphiles of the invention are active as transfectants without co- lipid. Accordingly, the practice of the present invention is neither to be considered limited by theories as to co-lipid participation in intracellular deliver ⁇ ' mechanisms, nor to require the involvement of co-lipids.
  • Transacylation Reactions Although heretofore unrecognized in the art, it has been determined also that certain co-lipids may react chemically with certain types of cationic amphiphiles under conditions of co-storage, there resulting new molecular species. Generation of such new species is believed to occur via mechanisms such as transacylation.
  • Figure 4 depicts a transacylation reaction involving spermine cholesterol carbamate(No.67) and DOPE, there resulting lyso PE species and multiple forms of particular acyl- cationic amphiphile ( designated No. 80). With respect to such reactions, the following remarks are of interest.
  • amphiphile No.67 With respect to use of amphiphile No.67, it has been observed that a mixture of amphiphile and DOPE, in chloroform solvent, does not appear to participate in such reactions. However, preparing the amphiphile and co-lipid in an aqueous solution where bilayer-containing structures such as liposomes can form will permit transacylation. Additionally, if amphiphile and co-lipid are dried down to a thin film, such as from chloroform (thereby placing the 2 species in intimate contact), then transacylation also occurs, possibly as a result of entropic effects. It is expected that these phenomena would also apply to lyophilized amphiphile /DOPE preparations.
  • amphiphile /DOPE preparations at very cold temperatures, such as -70 degrees C.
  • Preparation of amphiphile No. 67 as a mono, di, or tri acetate salt has also been determined to slow transacylations.
  • compositions of the present invention may or may not contain such transacylation byproducts, or other byproducts, and that the presence of such byproducts does not prevent the therapeutic use of the compositions containing them. Rather use of such compositions is within the practice of the invention, and such compositions and the novel molecular species thereof are therefore specifically claimed.
  • compositions of the invention provide for pharmaceutical compositions that facilitate intracellular delivery of therapeutically effective amounts of biologically active molecules.
  • Pharmaceutical compositions of the invention facilitate entry of biologically active molecules into tissues and organs such as the gastric mucosa, heart, lung, and solid tumors. Additionally, compositions of the invention facilitate entry of biologically active molecules into cells that are maintained in vitro , such as in tissue culture.
  • the amphiphilic nature of the compounds of the invention enables them to associate with the lipids of cell membranes, other cell surface molecules, and tissue surfaces, and to fuse or to attach thereto.
  • liposome a vesicle formed into a more or less spherical bilayer, that is stable in biological fluids and can entrap biological molecules targeted for intracellular delivery.
  • liposomal compositions permit biologically active molecules carried therewith to gain access to the interior of a cell through one or more cell processes including endocytosis and pinocytosis.
  • the cationic amphiphiles of the invention need not form highly organized vesicles in order to be effective, and in fact can assume (with the biologically active molecules to which they bind) a wide variety of loosely organized structures. Any of such structures can be present in pharmaceutical preparations of the invention and can contribute to the effectivenesss thereof.
  • Biologically active molecules that can be provided intracellularly in therapeutic amounts using the amphiphiles of the invention include: (a) polynucleotides such as genomic DNA, cDNA, and mRNA that encode for therapeutically useful proteins as are known in the art, (b) ribosomal RNA;
  • antisense polynucleotides whether RNA or DNA, that are useful to inactivate transcription products of genes and which are useful, for example, as therapies to regulate the growth of malignant cells;
  • ribozymes In general, and owing to the potential for leakage of contents therefrom, vesicles or other structures formed from numerous of the cationic amphiphiles are not preferred by those skilled in the art in order to deliver low molecular weight biologically active molecules. Although not a preferred embodiment of the present invention, it is nonetheless within the practice of the invention to deliver such low molecular weight molecules intracellularly. Representative of the types of low molecular weight biologically active molecules that can be delivered include hormones and antibiotics.
  • Cationic amphiphile species of the invention may be blended so that two or more species thereof are used, in combination, to facilitate entry of biologically active molecules into target cells and /or into subcellular compartments thereof.
  • Cationic amphiphiles of the mvention can also be blended for such use with amphiphiles that are known in the art.
  • Dosages of the pharmaceutical compositions of the invention will vary, depending on factors such as half-life of the biologically-active molecule, potency of the biologically-active molecule, half-life of the amphiphile(s), any potential adverse effects of the amphiphile(s) or of degradation products thereof, the route of administration, the condition of the patient, and the like. Such factors are capable of determination by those skilled in the art.
  • compositions of the invention A variety of methods of administration may be used to provide highly accurate dosages of the pharmaceutical compositions of the invention.
  • Such preparations can be administered orally, parenterally, topically, transmucosally, or by injection of a preparation into a body cavity of the patient, or by using a sustained-release formulation containing a biodegradable material, or by onsite delivery using additional micelles, gels and liposomes.
  • Nebulizing devices, powder inhalers, and aerosolized solutions are representative of methods that may be used to administer such preparations to the respiratory tract.
  • compositions of the invention can in general be formulated with excipients (such as the carbohydrates lactose, trehalose, sucrose, mannitol, maltose or galactose) and may also be lyophiiized (and then rehydrated) in the presence of such excipients prior to use.
  • excipients such as the carbohydrates lactose, trehalose, sucrose, mannitol, maltose or galactose
  • Conditions of optimized formulation for each amphiphile of the invention are capable of determination by those skilled in the pharmaceutical art.
  • spermidine cholesterol carbamate amphiphile No. 53
  • sucrose is preferred over mannitol in order to prevent formation of amphiphile /DNA aggregates, particularly as the concentration of DNA is increased therein.
  • a principal aspect of the invention involves providing a composition that comprises a biologically active molecule (for example, a polynucleotide) and one or more cationic amphiphiles (including optionally one or more co-lipids), and then maintaining said composition in the presence of one ore more excipients as aforementioned, said resultant composition being in liquid or solid (preferably lyophiiized) form, so that: (1) the therapeutic activity of the biologically active molecules is substantially preserved; (2) the transfection-enhancing nature of the amphiphile( or of amphiphile/ DNA complex) is maintained.
  • the excipients stabilize the interaction (complexes)of the amphiphile and biologically active molecule through one or more effects including:
  • an additional and valuable characteristic of the amphiphiles of the invention is that any such potentially adverse effect can be minimized owing to the greatly enhanced in vivo activity of the amphiphiles of the invention in comparison with amphiphilic compounds known in the art. Without being limited as to theory, it is believed that osmotic stress ( at low total solute concentration) may contribute positively to the successful transfection of polynucleotides into cells in vivo .
  • Such a stress may occur when the pharmaceutical composition, provided in unbuffered water, contacts the target cells.
  • Use of such otherwise preferred compositions may therefore be incompatible with treating target tissues that already are stressed, such as has damaged lung tissue of a cystic fibrosis patient. Accordingly, and using sucrose as an example, selection of concentrations of this excipient that range from about 15 mM to about 200 mM provide a compromise betweeen the goals of (1) stabilizing the pharmaceutical composition to storage and (2) mimizing any effects that high concentrations of solutes in the composition may have on transfection performance.
  • An additional aspect of the invention concerns the protonation state of the cationic amphiphiles of the invention prior to their contacting plasmid DNA in order to form a therapeutic composition. It is within the practice of the invention to utilize fully protonated, partially protonated, or free base forms of the amphiphiles in order to form such therapeutic compositions.
  • amphiphile No. 67 spermine cholesterol carbamate
  • DOPE itself provided as a zwitterion
  • transgene expression was best for the free base, but decreased if the amphiphile was prepared as an acetate salt.
  • Activity decreased step-wise through the mono and di acetate salts and was minimal for the triacetate salt.
  • the plasmid DNA provided for contacting with the amphiphile was prepared (without buffer) as a sodium salt in water.
  • a further aspect of the invention involves intravascular transfection of cells of tissues in a patient using a complex comprising one or more cationic amphiphiles of the invention and a therapeutic polynucleotide.
  • therapeutic polynucleotides include: (a) polynucleotides such as genomic DNA, cDNA, and mRNA that encode for therapeutically useful proteins as are known in the art, (b) ribosomal RNA;
  • antisense polynucleotides whether RNA or DNA, that are useful to inactivate transcription products of genes and which are useful, for example, as therapies to regulate the growth of malignant cells;
  • Blood vessels suitable for application in the practice of the invention include those of the arterial, venous, or capillary systems. It is also within the practice of the invention to administer therapeutic compositions through a vessel of the lymphatic system, or into tissue fluids in direct contact with the target tissue or organ.
  • the cationic amphiphiles of the invention can be formulated with co-lipids and polynucleotides for such therapeutic application.
  • the target tissue is preferably either highly vascularized, or contains atypical vascular organization.
  • highly vascularized tissue include those of the lung, liver, the heart, and the kidney.
  • atypical vascular organization include that which results from tumor cell infiltration, a chronic inflammatory state, or other disease process, wherein the nature or extent of the interface between the vascular system and the targeted tissue deviates from normal.
  • atypical vascularization of a target tissue provides an environment characterized by increased permeability or leakage, or otherwise makes the target tissue more accessibile to cationic amphiphile/polynucleotide complexes.
  • the target tissue contains tumor cells, the growth properties of which are controlled either by transfection into the tumor cells of an therapeutic polynucleotide, or for example, by the transfection of adjacent cells that express from an encoding DNA a regulatory protein having specificity for the tumor cells.
  • a further aspect of the invention involves contacting the vascular system of a patient with a composition that comprises a cationic amphiphile and a polynucleotide that encodes a protein having therapeutic properties, such that cells of the vascular system are transfected thereby, and express said protein from said polynucleotide.
  • the protein is one normally secreted from cells
  • the encoding polynucleotide includes, for example, sequences for pre- or pro-peptides, or for amino acids that are to be glycosylated, such that the encoded protein is secreted into the vascular circulation of a patient, after which the secreted protein provides therapeutic benefit at a site remote or adjacent to the transfected cells.
  • therapeutic proteins that can be expressed in patients according to this aspect of the invention include adenosine deaminease, glucoceribidase, and further include numerous of the protein hormones such as growth hormones, insulin and the like. Efficient expression of such a protein is demonstrated in Example 11.
  • amphiphiles 53, 67, 78, 90, and 91 are representative. Without being limited as to theory, it is believed that the incorporation into such molecules of polar head groups that include one ore more combinations of protonatable alkyl amine moieties [-NH- (CH2) ⁇ ]-wherein the "x's"thereof provide one or more combinations of 3 and of 4 carbon atoms leads to high in vivo transfection efficiency for plasmid transgenes complexed therewith.
  • these in-common structural features may have a useful effect upon the binding of the amphiphiles not only to DNA, but also on interaction with cell surface polyamine receptors, including those of tumor cells. Effecient transfection of tumor cells using such a cationic amphiphile is demonstrated in Example 12.
  • Nl, N8 - dicarbobenzoxyspermidine (61% yield, m.p. 104 - 105° C) was prepared according to the procedure of S. K. Sharma, M. J. Miller, and S. M. Payne, J. Med. Chem., 1989, 32, 357-367.
  • Nl, N ⁇ - dicarbobenzoxyspermidine (25 g , 60.5 mmol) and triethylamine (25 ml, 178 mmol) were dissolved in 625 ml of anhydrous methylene chloride, cooled to 0 - 4°C and stirred under N2- Cholesteryl chloroformate (27.2 g, 60.6 mmol) was dissolved in 250 ml of methylene chloride and added to the reaction over a 20 minute period. A white precipitate formed upon addition. After the addition was complete, the reaction was stirred at 0 - 4°C for 10 minutes and then at room temperature for 1.5 hr. At this point, the white precipitate completely dissolved.
  • the crude product was purified by column chromatography (2 kg silica gel, eluent - hexane / ethyl acetate 6 / 4) to give 46.8 g of the 3- ⁇ -[N4-(Nl,N8-dicarbobenzoxyspe ⁇ m iine)carbamoyl] cholesterol (also described herein as Nl, N& " diCBZ-N 4 - spermidine cholesterol carbamate) in 93% yield.
  • N 4 -spermine cholesteryl carbamate Spermine cholesterol carbamate ( Figure 1, No. 67) was prepared according to the following procedure which is outlined in Figure 9.
  • N ⁇ NI 2 -diCBZ-spermine Benzylchloroformate (1.76g, 1.5 ml, 10.36 mmol) was dissolved in methylene chloride (5 ml) and placed in a three neck flask under a nitrogen atmosphere.
  • Imidazole 1.4 g, 20.6 mmol
  • the mixture was stirred at room temperature for 1 hour and then methylene chloride ( 25 mL) and citric acid (10%, 25 ml) were added. The layers were separated and the organic fraction was washed with citric acid (10%, 25 ml). The organic component was dried over magnesium sulfate and concentrated in vacuo. The residue was dried under high vacuum for 1 hour at ambient temperature.
  • Nl ⁇ jl ⁇ diCBZ-N ⁇ spermine cholesteryl carbamate (262 mg, 0.300 mmol) was dissolved in 5 ml of acetic acid and 45 mg of 10% Pd on C was added. The solution was purged with nitrogen and stirred under hydrogen at atmospheric pressure. The hydrogenolysis was allowed to proceed for 7 hours. The reaction mixture was filtered and the catalyst was washed with 40 ml of ethyl acetate / acetic acid 9 / 1 and the filtrate will be concentrated in vacuo to give a residue. The crude product was dissolved in 35 L of IN NaOH and extracted three times with 40 ml of chloroform / methanol 9 / 1. The combined organic fractions were washed with 20 mL of water and dried over Na2SO4. The solution was filtered, concentrated in vacuo and dried under vacuum to give 125 mg of the desired product in 67% yield.
  • Urea analogs - such as spermine or spermidine cholestamine urea - can be prepared by a sequence of reactions well known to those versed in the art of organic synthesis. For example an amine can be treated with an equal molar amount of carbonyldiimidazole followed by the addition of a second amine to give the desired urea.
  • N,N Bis (3-aminopropyl)-O-cholesteryl-3-carbamate ( Figure 1, No. 69) was prepared according to the following procedure.
  • Bis (3-CBZ aminopropyl) amine was prepared using the method described above for N!,N12 -diCBZ-spermine, except that N-(3-aminopropyl)l,3-propanediamine was substituted for spermine as reactant.
  • the pure product was isolated in 34 % yield by silica gel flash chromatography using as solvent CHCI3/ MeOH/ NH4OH 80/20/0.5.
  • the Bis (3-CBZ aminopropyl) amine so prepared was then reacted with cholesteryl chloroformate according to the method described above for the synthesis of Nl, N ⁇ -DiCBZ -N ⁇ spermidine cholesteryl carbamate.
  • the pure product (N,N Bis ( 3-CBZ aminopropyl)-O-cholesteryl-3-carbamate) was obtained in 73% yield.
  • N.N Bis (6-aminohexyl)-O-cholesteryl -3- carbamate N,N Bis (6-aminohexyl)-O-cholesteryl-3-carbamate ( Figure 1, No. 70) was prepared according to the following procedure. First, Bis (6-CBZ aminohexyl) amine was prepared using the method described above for N1,N12 -diCBZ-spermine, except that Bis(hexamethylene)triamine was substituted for spermine as reactant. Pure product was isolated in 24% yield by recrystallization from toluene.
  • the 3-phthalimidocholestane (5.40 g, 9.75 mmol) was dissolved in 60 mL of methanol and anhydrous hydrazine (3.1 ml, 99 mmol) was added. The reaction mixture was stirred and heated at reflux under a nitrogen atmosphere for 4 hr. This mixture was then cooled to room temperature, 3.1 mL of concentrated HC1 was added and the resulting mixture was heated at reflux overnight. Upon cooling to ambient temperature, 100 ml of diethyl ether and 50 ml of 1 N NaOH were added (final pH of 10.1) and the layers were separated. The aqueous layer was extracted with 50 ml of diethyl ether and the combined organic fractions were filtered. The filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography (chloroform / methanol 90 / 10) to give 2.24 g of 3-aminocholestane in 59 % yield.
  • the filtrate was concentrated in vacuo and the residue was purified by chromatography on 25 g of silica gel (eluent - hexane / ethyl acetate 6 / 4, sample applied in hexane / ethyl acetate 9 / 1).
  • the purified material was dissolved in 25 mL of chloroform and HC1 gas was bubbled through the solution for 2 hr. followed by nitrogen for 10 min.
  • the solution was concentrated in vacuo to give 299 mg of the desired product in 79% yield as the dihydrochloride salt.
  • Nl j8-Bis(3-aminopropyl)-N 4 -spermidine cholesteryl carbamate (Figure 1, No. 75) was prepared according to the following procedure. N ⁇ -Spermidine cholesteryl carbamate (1.14g, 2.04 mmol) was dissolved in
  • the N ⁇ S-Bis (cyanoethyl) N ⁇ Spermidine cholesteryl carbamate. was dissolved in EtOH (35 mL) and added to the bomb.
  • the vesicle was evacuated and placed under Argon pressure (80-100 psi), three times and then evacuated and placed under Hydrogen pressure (100 psi), three times.
  • the reaction was stirred under hydrogen pressure (1Q0 psi) at room temperature for 72h.
  • the vesicle was evacuated and placed under argon pressure.
  • the catalyst was removed by filtration.
  • the filtrate was concentrated in vacuo .
  • the resulting oil was dissolved in 2:1 CH2Q2: MeOH (100 mL) and washed with H2O (35 and 25 mL).
  • N(N ⁇ -3-aminopropyl-spermidine cholesteryl carbamate N(N4-3-ammopropyl-spermidine) cholesteryl carbamate ( Figure 1, No. 78) was prepared as follows: Nl, N8-dicarbobenzoxyspermidine (1.0 g, 2.4 mmol) was dissolved in MeOH
  • N ⁇ -Cyanoethyl-Nl, N ⁇ -dicarbobenzoxyspermidine 0.5 g, 1.07 mmol
  • MeOH MeOH
  • C0CI2 280 mg, 2.15 mmol, Aldrich
  • NaBPLj 405 mg, 10.7 mmol, Aldrich
  • the black solution was stirred at room temperature for 1 h. The black solution turned blue over this period.
  • N 8 - dicarbobenzoxyspermidine 300 mg, 0.66 mmol
  • CH2CI2 Et3N
  • N2- Cholesteryl chloro formate 326 mg, 0.726 mmol, Aldrich
  • N-[Nl,N 4 ,N8"Tris (3-aminopropyl) spermidine] cholesteryl carbamate ( Figure 1, No. 96) was prepared by reacting N- ⁇ S-aminopropylspermidine) cholesteryl carbamate with acrylonitrile (90% yield) and subsequent reduction of the di adduct with Raney nickel (75 % yield) as described for the preparation of Nl,N8Bis(3-aminopropyl)-N4-spermidine cholesteryl carbamate.
  • N,N-Bis(4-aminobutyl cholesteryl carbamate N,N-Bis(4-aminobutyl) cholesteryl carbamate ( Figure 1, No. 82) was prepared as follows.
  • N,N-Bis (3-cyanopropyl) benzylamine (3.7 g, 17.8 mmol) was dissolved in EtOH (150 mL) and Acetic acid (4 mL) was added. This solution was added to 10% Pd on carbon (400 mg) under N2- The mixture was placed under H2 and the reaction stirred for 18 h at room temperature. The reaction was placed under N2- The catalyst was filtered off and washed with EtOH (150 mL). The filtrate was concentrated in vacuo , chloroform (50 mL) was added and again concentrated in vacuo . The resulting oil was vacuum dried for 0.5 h and used directly in the next reaction.
  • Raney Nickel 50% slurry (1.2 g) was placed in a Parr Bomb with IM NaOH in 95% EtOH (50 mL).
  • the N,N-Bis (3-cyanopropyl) cholesteryl carbamate (1.0 g, 1.77 mmol was dissolved in EtOH (100 mL) and added to the bomb.
  • the vesicle was evacuated and placed under Argon pressure (80-100 psi), three times and then evacuated and placed under Hydrogen pressure (100 psi), three times.
  • the reaction was stirred under hydrogen pressure (100 psi) at room temperature for four days.
  • the vesicle was evacuated and placed under argon pressure.
  • the catalyst was removed by filtration. The filtrate was concentrated in vacuo .
  • No. 83 was prepared by reacting N,N " Bis(4-arninobutyl) cholesteryl carbamate with acrylonitrile (82% yield) and subsequent reduction of the di acrylonitrile adduct with Raney nickel (81 % yield) as described for the preparation of Nl ,N&- Bis(3-aminopropyl)-N 4 -spermidine cholesteryl carbamate.
  • the layers were separated and the aqueous layer was extracted with diethyl ether (100 mL). The combined organic layers were washed with a solution of Sodium thiosulfate pentahydrate(120 mg) in H2O (30 mL). The organic layer was concentrated in vacuo and vacuum dried for 18 h. The crude solid was titrated with hexanes (25 mL). After filtration the solid was washed with ice cold hexanes (10 mL). The solid was vacuum dried for lh. The cholesteryl carboxylic acid obtained (3.0 g, 59 %) was ca. 90 % pure and used without further purification.
  • N,N-dioctadecyllysineamide N,N- dioctadecyllysineamide( Figure 6, No.73) was prepared according to the following procedure. N,N-dioctadecylamine (1.35 g, 2.58 mmol, Fluka) and L-N ⁇ ,N ⁇ -diBOClysine N-hydroxysuccinimide ester ( 1.00 g, 2.58 mmol, Sigma) were combined in 15 ml of methylene chloride and 2 ml triethylamine was added. The reaction mixture was heated briefly to effect complete dissolution and then stirred at ambient temperature overnight.
  • the organic layer was separated, dried over magnesium sulfate, filtered and reduced in vacuo to a white solid
  • the crude material was purified by flash column chromatography (125 g silica gel) eluting with 90: 10: 0.5 chloroform/ methanol/ ammonium hydroxide.
  • the desired product was isolated as an oil and characterized by iH NMR as 1-(N 4 - (N 1,N 12-di-CBz-spermine))-2,3-dilaurylglycerol carbamate (188 mg, 15%).
  • the organic layer was separated, dried over magnesium sulfate, filtered and reduced in vacuo to an oil.
  • the product was characterized by iH NMR as l-(N 4 -spermine)-2,3- dilaurylglycerol carbamate (125 mg, 94%).
  • amphiphiles of the invention may be prepared according to procedures that are within the knowledge of those skilled in art. Examples The following Examples are representative of the practice of the invention.
  • amphiphile No. 53 spermidine cholesterol carbamate
  • DOPE neutral lipid dioleoylphosphatidylethanolamine
  • a thin film was produced by removing chloroform from the mixture by evaporation under reduced pressure (20 mm Hg). The film was further dried under vacuum (1 mm Hg) for 24 hours.
  • some of the amphiphiles of the invention participate in transacylation reactions with co-lipids such as DOPE, or are subject to other reactions which may cause decomposition thereof. Accordingly, it is preferred that amphiphile /co-lipid compositions be stored at low temperature, such as -70 degrees C, until use.
  • the lipid film was then hydrated with sterile deionized water (1 ml) for 10 minutes, and then vortexed for 1 minute ( sonication for 10 to 20 seconds in a bath sonicator may also be used, and sonication has proved useful for other amphiphiles such as DC-chol).
  • the resulting suspension was then diluted with 4 ml of water to yield a solution that is 670 ⁇ M in cationic amphiphile and 670 ⁇ M in neutral colipid.
  • spermine cholesterol carbamate Experiments were also performed using spermine cholesterol carbamate
  • amphiphile No. 67 amphiphile No. 67
  • spermine cholesterol carbamate the optimum molar ratio of amphiphile to DOPE under the conditions tested was determined to be 1:2, not 1:1.
  • Optimized ratios for many of the amphiphiles of the invention are reported in Figures 13, 14 and 15, and are readily determined by those skilled in the art.
  • DNA encoding for ⁇ - galactosidase (pCMN ⁇ , ClonTech., Palo Alto, CA) was dissolved in OptiMEM culture medium (Gibco/ BRL No.31885-013).
  • OptiMEM culture medium Gibco/ BRL No.31885-013
  • the resulting solution had a DNA concentration of 960 ⁇ M (assuming an average molecular weight of 330 daltons for nucleotides in the encoding DNA).
  • DOPE DOPE.
  • a 165 ⁇ l aliquot of spermidine cholesterol carbamate (670 ⁇ M) containing also the colipid ( at 670 ⁇ M ) was pipetted into 8 separate wells in a 96-well plate containing OptiMEM (165 ⁇ l) in each well.
  • the resulting 335 ⁇ M solutions were then serially diluted 7 times to generate 8 separate arnphiphile-containing solutions having concentrations ranging from 335 ⁇ M to 2.63 ⁇ M, with each resultant solution having a volume of 165 ⁇ l.
  • 64 solutions were prepared in all, there being 8 wells each of 8 different concentrations of amphiphile /DOPE.
  • DNA solutions (165 ⁇ l, 960 ⁇ M) were pipetted into 8 wells containing OptiMEM (165 ⁇ l), and the resulting 480 ⁇ M solutions were then serially diluted 7 times to generate 8 separate 165 ⁇ l solutions from each well, with the concentrations of DNA in the wells ranging from 480 ⁇ M to 3.75 ⁇ M.
  • the 64 test solutions (cationic amphiphile: neutral lipid) were then combined with the 64 DNA solutions to give separate mixtures in 64 wells, each having a volume of 330 ⁇ l, with DNA concentrations ranging from 240 ⁇ M to 1.875 ⁇ M along one axis, and lipid concentrations ranging from 167 ⁇ M to 1.32 ⁇ M along the other axis.
  • 64 solutions were prepared in all, each having a different amphiphile: DNA ratio and /or concentration.
  • the solutions of DNA and amphiphile were allowed to stand for 15 to 30 minutes in order to allow complex formation.
  • a CFT-1 cell line human cystic fibrosis bronchial epithelial cells immortalized with papillomavirus
  • CFTR cystic fibrosis transmembrane conductance regulator
  • the ⁇ F508 mutation is the most common mutation associated with cystic fibrosis disease.
  • the properties of the ⁇ F508 mutation and the genetics of cystic fibrosis disease see, in particular, Cheng et al., Cell. 63, 827-834 (1990). See also Riordan et al., Science. 245. 1066-1073 (1989); published European Patent Application No. 91301819.8 of Gregory et al., bearing publication number 0446 017 Al; and Gregory et al., Nature.347, 382-385 (1990).
  • the cells were cultured in Hams F12 nutrient media (Gibco/ BRL No. 31765-027) supplemented with 2% fetal bovine serum ("FBS", Irvine Scientific, No. 3000) and 7 additional supplements. Cells were then plated into 96-well tissue culture plates at a density of approximately 7,500 cells /well. Before being used in the assay, cells were allowed to grow for periods of 5-7 days until a confluent pattern had been achieved.
  • Hams F12 nutrient media Gibco/ BRL No. 31765-027
  • FBS fetal bovine serum
  • the resultant medium was removed from the plates and the cells washed with phosphate buffered saline. Lysis buffer (50 ⁇ l, 250 mM Tris- HCl, pH 8.0, 0.15% Triton X-100) was then added, and the cells were lysed for 30 minutes. The 96-well plates were carefully vortexed for 10 seconds to dislodge the cells and cell debris, and 5 ⁇ l volumes of lysate from each well were transferred to a plate containing lOO ⁇ l volumes of Coomassie Plus® protein assay reagent (Pierce Company, No.23236). The protein assay plates were read by a Bio-Rad Model 450 plate-reader containing a 595nm filter, with a protein standard curve included in every assay.
  • Lysis buffer 50 ⁇ l, 250 mM Tris- HCl, pH 8.0, 0.15% Triton X-100
  • the level of ⁇ -galactosidase activity in each well was measured by adding phosphate buffered saline (50 ⁇ l) to the remaining lysates, followed by addition of a buffered solution consisting of chlorophenol red galactopyranoside (100 ⁇ l, 1 mg per ml, Calbiochem No. 220588), 60 mM disodium hydrogen phosphate pH 8.0, 1 mM magnesium sulfate, 10 mM potassium chloride, and 50 mM 2- mercaptoethanol.
  • the chlorophenol red galactopyranoside following enzymatic ( ⁇ -galactosidase) hydrolysis, gave a red color which was detected by a plate- reader containing a 570 nm filter.
  • a ⁇ -galactosidase (Sigma No. G6512) standard curve was included to calibrate every assay.
  • CFT-1 Immortalized human cystic fibrosis airway cells
  • the cells were grown on glass coverslips until approximately 60% confluent. The cells were then transfected with a complex of spermidine cholesterol carbamate:DOPE (1:1) and a plasmid(pCMN- CFTR) containing a cD ⁇ A that encodes wild type human CFTR.
  • pCMV-CFTR plasmid is a construct containing the encoding sequence for CFTR and the following regulatory elements, a CMV promoter and enhancer, and an SV40 polyadenylation signal. Additional constructs suitable for the practice of this example include pMT-CFTR, Cheng et al., £e ⁇ 63, 827-834 (1990). The complex used was 10.5 ⁇ molar of spermidine cholesterol carbamate (also of DOPE) and 30 ⁇ molar of pCMV-CFTR based on nucleotide.
  • Fluorescence of the SPQ molecule in individual cells was measured using an inverted microscope, Nikon, , a digital imaging system from Universal Imaging, and an ICCD camera, Hamamatsu, Inc.. Cells were selected for analysis without prior knowledge of their expected rate-of-change- in-fluorescence characteristics.
  • spermidine cholesterol carbamate, and other cationic amphiphiles of the invention similarly tested, are effective in transferring CFTR-encoding plasmid into immortalized CF airway cells.
  • This assay was used to assess the ability of the cationic amphiphiles of the invention to transfect cells in vivo from live specimens.
  • the lungs of balb/c mice were instilled intra-nasally (the procedure can also be performed trans-tracheally) with 100 ⁇ l of cationic amphiphile:DNA complex, which was allowed to form during a 15-minute period prior to administration according to the following procedure.
  • the amphiphile (premixed with co-lipid, see below) was hydrated in water for 10 minutes, a period sufficient to yield a suspension at twice the final concentration required. This was vortexed for two minutes and aliquoted to provide 55 microliter quantities for each mouse to be instilled.
  • DNA encoding the reporter (CAT) gene was diluted with water to a concentration twice the required final concentration, and then aliquoted at 55 microliters for each mouse to be instilled. The lipid was gently combined with the DNA (in a polystyrene tube), and the complex allowed to form for 15 minutes before the mice were instilled therewith.
  • the plasmid used (pCMVHI-CAT, see Example 4) provides an encoding D ⁇ A for chloramphenicol transferase enzyme. Specifics on the amphiphile:D ⁇ A complexes are provided below.
  • mice Two days following transfection, mice were sacrificed, and the lungs and trachea removed, weighed, and homogenized in a buffer solution (250 mM Tris, pH 7.8, 5mM EDTA). The homogenate was clarified by centrifugation, and the deacetylases therein were inactivated by heat treatment at 70 °C for 10 minutes. Lysate was incubated overnight with acetyl coenzyme A and C I 4 — chloramphenicol. CAT enzyme activity was then visualized by thin layer chromatography ("TLC") following an ethyl acetate extraction. Enzyme activity was quantitated by comparison with a CAT standard curve.
  • TLC thin layer chromatography
  • the presence of the enzyme CAT will cause an acetyl group to be transferred from acetylcoenzyme A to C I 4 —chloramphenicol.
  • the acetylated/radiolabeled chloramphenicol migrates faster on a TLC plate and thus its presence can be detected.
  • the amount of CAT that had been necessary to generate the determined amount of acetylated chloramphenicol can then be calculated from standards.
  • the activity of spermidine cholesterol carbamate (amphiphile No.53) was determined in the CAT assay in relation to the recognized transfection reagents DMRIE and DC-Choi.
  • Figure 10 demonstrates dramatically (as ng CAT activity per 100 mg tissue) the enhanced ability of spermidine cholesterol carbamate (amphiphile No. 53) to transfect cells in vivo, which enhancement is about 20- fold, or greater, in this assay.
  • activity was measured as ng CAT enzyme per 100 mg lung tissue.
  • DMRLE a well known transfectant
  • plasmid DNA 1.7 mM DMRLE, 1.7 mM DOPE, 1.2 mM plasmid DNA measured as nucleotide
  • the transfection solution for spermidine cholesterol carbamate contained 6mM DNA measured as concentration of nucleotide, and 1.5 mM of cationic amphiphile.
  • each amphiphile had also been premixed with DOPE, in this case at 1:1 molar ratio.
  • the molar ratio of DC-chol to DOPE was 3:2, and the concentrations of cationic amphiphile and of DNA (as nucleotide) were 1.3 mM and 0.9 mM, respectively.
  • the molar ratio of DMR E to DOPE was 1:1 and the concentrations of cationic amphiphile and of DNA were 1.7 mM and 1.2 mM, respectively. These concentrations (and concentration ratios) for each amphiphile, and colipid and DNA, had been determined to be optimal for transfection for that respective amphiphile, and accordingly were used as the basis for the comparison presented herein.
  • concentrations (and concentration ratios) for each amphiphile, and colipid and DNA had been determined to be optimal for transfection for that respective amphiphile, and accordingly were used as the basis for the comparison presented herein.
  • spermidine cholesterol carbamate amphiphile No. 53
  • optimization experiments were also performed to determine preferred concentrations of plasmid for a particular amphiphile concentration (see Figure 11), and also to determine preferred concentrations of the same amphiphile in relation to a particular plasmid concentration (see Figure 12).
  • Transfection efficiency was optimal at an amphiphile concentration of 1.5 mM (DOPE also being present at 1.5 mM), and about 6 mM (by nucleotide) of plasmid, or about at a ratio of 1:4. It was noted, however, that concentrations of about 0.75 mM of amphiphile, and 3.0 mM of plasmid were less toxic to the target cells.
  • Intra-nasal transfection with pCMVHI-CAT vector was also performed in mice using spermidine cholesterol carbamate as cationic amphiphile but with cholesterol as co-lipid.
  • concentrations of spermidine cholesterol carbamate tested were between 1.0 and 1.5 mM (cholesterol being present at a 1:1 molar ratio in each case, with the mixing of amphiphile and co- lipid being performed as above).
  • the DNA concentration was between 4.0 and 6.0 mM.
  • Transfection efficiency (again measured as ng CAT/100 mg tissue) was less effective than with DOPE as co-lipid; however, the transfections were substantially more effective than those achieved using DC-Chol/DOPE. part B
  • the ratio, for in vivo testing, of amphiphile concentration to DOPE concentration was taken from the in vitro experiments, as was the optimized ratio of amphiphile concentration to DNA concentration (see Example 1). Accordingly, for such amphiphiles the in vivo test concentration was fixed at lmM, thereby fixing also the co-lipid concentration.
  • the molar ratio of the amphiphile to co-lipid DOPE ranged from 1:2 (for example, spermine cholesterol carbamate, No. 67) through 1:1 (for example, spermidine cholesterol carbamate, No. 53) to about 2:1 (for example, amphiphile No. 75)].
  • the concentration of plasmid DNA varied for each amphiphile species tested in order to duplicate the optimized amphiphile /DNA ratio that had been determined in vitro. part C
  • novel amphiphiles of the invention are an important contribution to the art is immediately seen by comparing their performance - as in vivo transfection enhancers - to that of closely related cationic amphiphiles that lack the novel T-shape. It has been determined that spermidine cholesterol carbamate provides a much greater level of enhancement than N i -spermidine cholesteryl carbamate which contains the same number of carbon and nitrogen atoms in its cationic alkylamine component but which is linear and not "T-shaped".
  • Example 3 Following generally the procedures of Example 3, part B, and using respectively 6mM (as nucleotide), 1.5 mM, and 1.5 mM concentrations of DNA, amphiphile and of co-lipid, the transfection enhancement provided by spermidine cholesterol carbamate (amphiphile No.53) , in relation to N 1 -spermidine cholesteryl carbamate, was determined to be about 30 fold.
  • Example 4 Construction of vectors
  • the biologically active macromolecule is an encoding DNA.
  • plasmids novel vectors
  • part A pCMVHI-CAT
  • pCMVHI-CAT is representative of plasmid constructs useful in the practice of the invention.
  • the plasmid is provided in a form carrying a reporter gene (see Example 3), transgenes having therapeutic utility may also be included therein.
  • the pCMVHI-CAT vector is based on the commercially available vector pCMN ⁇ (Clontech).
  • the pCMN ⁇ construct has a pUC19 backbone (]. Vieira, et al., Gene , 19, 259-268, 1982) that includes a procaryotic origin of replication derived originally from pBR322.
  • Basic features of the pCMNHI-CAT plasmid (as constructed to include a nucleotide sequence coding for CAT) are as follows.
  • the human cytomegalovirus immediate early gene promoter and enhancer spans the region from nucleotides 1-639. This corresponds to the region from -522 to +72 relative to the transcriptional start site (+1) and includes almost the entire enhancer region from -524 to -118 as originally defined by
  • the CAAT box is located at nucleotides 487- 491 and the TATA box is at nucleotides 522-526 in pCMVHI-CAT.
  • the CAT transcript is predicted to initiate at nucleotide 549, which is the transcriptional start site of the CMV promoter.
  • the tripartite leader-hybrid intron is composed of a fused tri-partite leader from adenovirus containing a 5' splice donor signal, and a 3' splice acceptor signal derived from an IgG gene.
  • the elements in the intron are as follows: the first leader, the second leader , part of the third leader, the splice donor sequence and intron region from the first leader, and the mouse immunoglobulin gene splice donor sequence.
  • the length of the intron is 230 nucleotides.
  • the CAT coding region comprises nucleotides 1257-1913.
  • the SV40 poly A signal extends from nucleotide 2020 to 2249.
  • construction of the pCMVHI-CAT plasmid proceeded as follows.
  • the vector pCMN ⁇ (Clontech, Palo Alto, CA) was digested with Not I to excise the ⁇ -galactosidase gene.
  • the vector fragment lacking the ⁇ -galactosidase gene was isolated and ligated to form pCMV.
  • the hybrid intron ( Figure 17) was obtained from the plasmid pAD ⁇ (Clontech). The hybrid intron had been isolated from a 695 base pair XhoI-EcoRI fragment of p91023(B), see Wong et al., Science.228, 810-815 (1985). The hybrid intron contains the fused tripartite leader from adenovirus, the donor site from the first segment of the tripartite leader, and the acceptor site from an IgG gene, and has a length of 230 bp.
  • pAD ⁇ was digested with Pml I and Not I, and the -500 base-pair (bp) fragment was isolated, and then ligated into the Not I site of pBluescriptH KS(-) (Stratagene, La Jolla, CA) to form pBlueH-HI.
  • pBlueH-HI was digested with Xhol and Notl to excise the hybrid intron fragment. This fragment was ligated into the Xhol and Notl sites of pCMN, replacing the SV40 intron to form pCMVHI.
  • the CAT gene was obtained from the Chloramphenicol Acetyltransferase GenBlock (Pharmacia, Piscataway, ⁇ J). This 792 bp Hind LH fragment was blunted with the Klenow fragment of D ⁇ A Polymerase I, then Not I linkers (New England Biolabs) were ligated to each end. After digestion with Not I to expose the Not I sticky ends, the fragment was subcloned into the Not I site of pCMN to form pCMV-CAT. pCMV-CAT was digested with Not I to excise the CAT fragment. The CAT fragment was ligated into pCMVHI to form pCMVHI- CAT which is depicted in Figure 16.
  • part B pCFl and pCF2
  • pCMVHI is suitable for therapeutic transfections
  • further performance enhancements including increased expression of transgenes
  • a map of pCFl/CAT is shown in Figure 18, panel A, and a map of pCF2/CAT is shown in panel B.
  • pCFl contains the enhancer/promoter region from the immediate early gene of cytomegalovirus (CMV) .
  • CMV cytomegalovirus
  • a hybrid intron is located between the promoter and the transgene cDNA.
  • the polyadenylation signal of the bovine growth hormone gene was selected for placement downstream from the transgene.
  • the vector also contains a drug-resistance marker that encodes the aminoglycosidase 3'-phosphotransferase gene (derived from the transposon Tn903, A. Oka et al., Tournal of Molecular Biology , 147, 217-226, 1981) thereby conferring resistance to kanamycin. Further details of pCFl structure are provided directly below, including description of placement therein of a cDN A sequence encoding for cystic fibrosis transmembrane conductance regulator (CFTR) protein.
  • CMV cytomegalovirus
  • the pCFl vector is based on the commercially available vector pCMV ⁇ (Clontech).
  • the pCMN ⁇ construct has a pUC19 backbone (J. Vieira, et al., Gene , 19, 259-268, 1982) that includes a procaryotic origin of replication derived originally from pBR322.
  • pCFl-plasmid (as constructed to include a nucleotide sequence coding for CFTR) are as follows. Proceeding clockwise — the human cytomegalovirus immediate early gene promoter and enhancer, a fused tripartite leader from adenovirus and a hybrid intron, a linker sequence, the CFTR cD ⁇ A, an additional linker sequence, the bovine growth hormone polyadenylation signal, pUC origin of replication and backbone, and the kanamycin resistance gene. The pCFl-CFTR plasmid has been completely sequenced on both strands. The human cytomegalovirus immediate early gene promoter and enhancer spans the region from nucleotides 1-639.
  • the CAAT box is located at nucleotides 486-490 and the TATA box is at nucleotides 521-525 in pCFl-CFTR.
  • the CFTR transcript is predicted to initiate at nucleotide 548, which is the transcriptional start site of the CMV promoter.
  • the hybrid intron is composed of a fused tri-partite leader from adenovirus containing a 5' splice donor signal, and a 3' splice acceptor signal derived from an IgG gene.
  • the elements in the intron are as follows: the first leader (nucleotides 705-745), the second leader (nucleotides 746-816), the third leader (partial, nucleotides 817-877), the splice donor sequence and intron region from the first leader (nucleotides 878-1042), and the mouse immunoglobulin gene splice donor sequence (nucleotides 1043-1138).
  • the donor site (G 1 GT) is at nucleotides 887-888, the acceptor site ( A£ I G) is at nucleotides 1128-1129 , and the length of the intron is 230 nucleotides.
  • the CFTR coding region comprises nucleotides 1183-5622.
  • the 3' untranslated region of the predicted CFTR transcript comprises 51 nucleotides of the 3' untranslated region of the CFTR cDNA, 21 nucleotides of linker sequence and 114 nucleotides of the BGH poly A signal.
  • the BGH poly A signal contains 90 nucleotides of flanking sequence 5' to the conserved AAUAAA and 129 nucleotides of flanking sequence 3' to the AAUAAA motif.
  • the primary CFTR transcript is predicted to be cleaved downstream of the BGH polyadenylation signal at nucleotide 5808.
  • pCF2 plasmid Figure 18 (B) contains a second CMV enhancer, in tandem with the first.
  • Enhanced expression of transgenes from pCFl or pCF2 results from the combination of a strong promoter, the presence of a highly efficient polyadenylation signal, a leader sequence that enhances translation, and an intron to increase message stability.
  • amphiphile spermidine cholesterol carbamate
  • DOPE dimethylcellulose
  • pCMV-CFTR plasmid vector a construct encoding wild type human cystic fibrosis transmembrane conductance regulator protein, see above. Concentrations in the final mixture were 42 ⁇ molar of spermidine cholesterol carbamate(and also of DOPE) and 60 ⁇ molar (based on molarity in nucleotides) of the plasmid expression vector.
  • CFTR CFTR-stimulated rransepithelial chloride secretion in a modified Ussing chamber, Zabner et al., Nature Genetics ,6, 75-83 (1984).
  • the mucosal side of the epithelium was bathed in Ringer's bicarbonate solution bubbled with 95% O2 and 5% CO2.
  • the composition of the submucosal solution was similar to the mucosal solution with the exception that sodium gluconate replaced sodium chloride.
  • Transepithelial voltage was clamped to 0 mV and short circuit current was recorded.
  • a recommended procedure for formulating and using the pharmaceutical compositions of the invention to treat cystic fibrosis in human patients is as follows.
  • Example 2 Following generally the procedures described in Example 1, a thin film (evaporated from chloroform) is produced, wherein spermine cholesterol carbamate (amphiphile No. 67) and DOPE are present in the molar ratio of 1: 2.
  • the amphiphile-containing film is rehydated in water-for -injection with gentle vortexing to a resultant amphiphile concentration of about 3mM.
  • amphiphile-containing film in order to increase the amount of amphiphile /DNA complex that may be stably delivered by aerosol as a homogeneous phase (for example, using a Puritan Bennett Raindrop nebulizer from Lenexa Medical Division, Lenexa, KS, or the PARI LC JetTM nebulizer from PARI Respiratory Equipment, Inc., Richmond, VA), it may be advantageous to prepare the amphiphile-containing film to include also one or more further ingredients that act to stablize the final amphiphile /DNA composition. Accordingly, it is presently preferred to prepare the amphiphile-containing film as a 1: 2 : 0.05 molar mixture of amphiphile No.
  • PEG-DMPE polyethylene glycol 5000 - dimyristoylphoshatidyl ethanolamine, is Catalog No. 880210 from Avanti Polar Lipids, Alabaster, AL]. Additional fatty acid species of PEG-PE may be used in replacement therefor.
  • PEG (5000) -DMPE is believed to stablize the therapeutric compositions by preventing further agrregation of formed amphiphile /DNA complexes. Additionally it is noted that PEG(2000)- DMPE was found to be less effective in the practice of the invention.
  • pCFl-CFTR plasmid (containing an encoding sequence for human cystic fibrosis transmembrane conductance regulator, see Example 4) is provided in water-for-injection at a concentration, measured as nucleotide, of 4 mM. Complexing of the plasmid and amphiphile is then allowed to proceed by gentle contacting of the two solutions for a period of 10 minutes.
  • aerosolized DNA it is presently preferred to deliver aerosolized DNA to the lung at a concentration thereof of between about 2 and about 12 mM (as nucleotide).
  • a sample of about 10 to about 40 ml is generally sufficient for one aerosol administration to the lung of an adult patient who is homozygous for the ⁇ F508 mutation in the CFTR-encoding gene.
  • cationic amphiphiles of the present invention are substantially more effective — in vivo — than other presently available amphiphiles, and thus may be used at substantially lower concentrations than known cationic amphiphiles. There results the opportunity to substantially minimize side effects (such as amphiphile toxicity, inflammatory response) that would otherwise affect adversely the success of the gene therapy.
  • amphiphiles of the invention A further particular advantage associated with use of many of the amphiphiles of the invention should again be mentioned. Many of the amphiphiles of the invention were designed so that the metabolism thereof would rapidly proceed toward relatively harmless biologically-compatible components. In this regard, highly active amphiphiles 53, 67, and 75 are of particular note.
  • plasmids for gene therapy also be able to replicate in the cells of patients, since continued presence of the plasmid will provide correction of the genetic defect (in the case of cystic fibrosis, lack of functioning CFTR protein in the cell membrane of lung epithelial cells or other cells) over an extended period of time.
  • plasmids representative of the current art that is, those that cannot replicate in the targeted cells of a patient
  • plasmids gene therapy vectors
  • One such strategy is to construct a plasmid capable of being maintained separately in the nucleus of a target cell, and that is also able to replicate there (i.e. an episome).
  • Plasmids provided according to this aspect of the invention can be constructed as follows. It has been determined (C. McWhinney et al., Nucleic Acids Research. 18, 1233-1242, 1990) that the 2.4 kb HindlH-XhoI fragment that is present immediately 5' to exon 1 of the human c-myc gene contains an origin of replication. The fragment was then cloned into a plasmid . that if transfected into HeLa cells was shown to persist therein for more than 300 generations under drug selection. Replication was shown to be semiconservative (C. McWhinney et al.). Although approximately 5% of the plasmid population was lost per cell generation without drug selection in those experiments, this result nonetheless demonstrates substantial stabilization would be of benefit with respect to the design of therapeutic plasmids for gene therapy.
  • a variant of pCFl-CFTR (or pCFl-CAT) can be constructed in which a copy of the 2.4 kb
  • HindHI-XhoI fragment is placed just 5' to the CMV enhancer /promoter region of the pCFl backbone. Alternatively, between 2 and about 4 - in tandem - copies of the 2.4 kb fragment may be similarly positioned.
  • the increase in plasmid size that results from insertion of the 2.4 kb fragment (or multiple copies thereof) is predicted to provide an additional benefit, that is, to facilitate plasmid unwinding, thus facilitating the activity of DNA polymerase.
  • Use of this origin of replication, or multiple copies thereof, allows the resultant plasmid to replicate efficiently in human cells.
  • Other DNA sequences containing other origins of replication may also be used (for example, as found in the human ⁇ -globin gene, or the mouse DHFR gene.
  • a plasmid that can be constructed according to this aspect of the invention and containing the cytomegalovirus promoter and enhancer, an intron, the CFTR cDNA, the bovine growth hormone polyadenylation signal, the kanamycin resistance transposon Tn903, and 4 copies of the 2.4 kb 5' flanking region of the human c-myc gene is shown in Figure 20.
  • Example 8- Further Enhancements in Plasmid Design for Gene Therapy :
  • Chronic inflammation is associated with numerous of the disease states that can be treated by gene therapy.
  • Representative of such disease states are cystic fibrosis (using CFTR), bronchitis, adult respiratory distress syndrome (using alpha-1 antitrypsin), and metastatic cancers (through upregulation of p53, TLMP-1, and TLMP-2).
  • Inflammatory conditions typically involve many interrelated processes (for example, involvement by many types of immune system cells and liver proteins), whereby the body attempts to heal a damaged or infected tissue.
  • chronic inflammation which persists as a result of an unresolved condition may lead to permanent tissue damage, as is the case with respect to lung tissue affected by cystic fibrosis and associated and unresolved lung infections.
  • a further aspect of the present invention involves construction of gene therapy vectors in which the therapeutic transgene is placed under control of an RNA polymerase promoter from a cytokine gene (or a gene that encodes another similar regulatory protein) such as, for example, the promoter for any of interleukin 2, interleukin 8, interleukin 1, interleukin 11, interleukin 6, endothelin -1, monocyte chemoattractant protein -1, IL-lra (receptor agonist), or for GM-CSF.
  • a cytokine gene or a gene that encodes another similar regulatory protein
  • Cytokines may be defined as hormone-like intercellular signal proteins that are involved in regulation of cell proliferation, differentiation, and function, such as concerning haematopoiesis and lymphopoiesis.
  • the interleukins are a particular group of cytokines having promoters that are useful in the practice of the invention.
  • the interleukins are proteins, typically of unrelated origin, which act as intercellular signals mediating reactions between immunoreactive cells. However, it is understood that many "interleukins" have effects upon additional cell types including endothelial cells, epithelial cells, and fibroblasts.
  • gene therapy vectors can be designed wherein the level of therapeutic transgene expressed therefrom is determined, in part, by the level of inflammation present. There follows hereafter description of how such vectors are designed using primarily properties of the interleukin 8 gene as an example.
  • interleukin 8 a polypeptide of 8,500 MW, is upregulated by inflammation and acts as a potent chemoattractant for T lymphocytes and neutrophil cells that are themselves involved in the inflammation response.
  • the interleukin 8 gene is regulated primarily at the transcriptional level, and it has also been determined (H.
  • TNF can increase interleukin 8 transcription by more than 30 -fold in vitro in bronchial epithelial cells. Accordingly, there follows description of gene therapy vectors which take advantage of the above.
  • a plasmid can be constructed that is substantially similar to pCFl, that is, derived from a pUC plasmid containing a bacterial-derived origin of replication and a gene conferring resistance to kanamycin.
  • the resultant plasmid contains also, in sequence, a CMV enhancer, a promoter, a hybrid intron, a cDNA sequence encoding CFTR, and the bovine growth hormone polyadenylation signal.
  • RNA polymerase promoter there is selected the -335 to +54 region of the interleukin 8 promoter. This region gave the highest ratio in terms of promoter activity plus TNF over minus TNF (Nakamura, 1991) Such a plasmid has particularly valuable performance attributes.
  • RNA polymerase promoter sequences derived from the other aforementioned genes are also useful in the practice of the invention.
  • Example 9 Intravenous Delivery of Transgenes For some disease states, such as cystic fibrosis, it is desirable to deliver transgenes to the lung. Delivery by aerosol is the most direct approach to achieve this goal. However, given the difficulties inherent with the delivery of an aerosol together with the potential need to target organs other than the lung (for example, the pancreas for cystic fibrosis), it is important to evaluate the feasibility of lung delivery using non-aerosol delivery formats. Accordingly, intravenous delivery of a reporter transgene was performed using a mouse model and the feasibility of intravenous organ targeting was assessed. A comparison was made of feasibility of delivery to the lung and the heart.
  • the reporter plasmid pCF-1 CAT (Example 4) was used and was purified to minimize endotoxin ( ⁇ 1 EU/mg pDNA), and also chromosomal DNA contamination ( ⁇ 2%).
  • Amphiphile No. 53 (1:1 with DOPE) / DNA complex was prepared according to the procedures of Example 3. The amphiphile was provided as the free base, the plasmid was prepared as a sodium salt in water, and the DOPE was provided in zwitterionic form.
  • the animal model was the BALB/c mouse. Females 6-8 weeks old weighing 16-18 g were injected intravenously using the tail vein, using 5 animals per group. The volume of lipid:pDNA complex used was 100 ⁇ l in all experiments.
  • mice were sacrificed 48 h following adminstration of the complex. Organs were frozen immediately on dry ice to store for subsequent analysis. Expression of chloramphenicol acetyl transferase (CAT) was quantitated using a radiochemical assay for CAT enzymatic activity. Organs were weighed and homogenized on ice in a lysis buffer containing protease inhibitors. The lysate was freeze-thawed 3X, centrifuged, and heated to 65°C to inactivate deacetylases before adding it to a reaction mixture containing l 4 C-chloramphenicol.
  • CAT chloramphenicol acetyl transferase
  • the DNA solution (1.5 mL) can then be added to an equal volume of cationic lipid vesicles and incubated at room temperature for 10 min. Enough NaCl (for example, 4 mM stock) may be added to result in a final concentration of 1 mM NaCl. If necessary, the sample can be diluted further with 1 mM NaCl (to maintain a photomultiplier signal below 4000 counts per second), and distilled water can be used in place of the NaCl solutions. According to this aspect of the invention, amphiphiles No. 53 and
  • Nljjl2-diCbz-N ⁇ -spermine cholesteryl carbamate (Synthesis of Nljjl2-diCbz-N ⁇ -spermine cholesteryl carbamate) Nl jl2-diCbz-spermine di HCl salt (13.38g, 24.7 mmol) was dissolved in a chloroform, methanol and water mixture in the ratio 65:25:4 (940 mL). The solution was stirred at room temperature and cholesteryl chloroformate (llg, 24.5 mmol) was added. The solution was stirred at ambient temperature for 1.5 hours and then diluted with IM sodium hydroxide solution (165 L). The organic and aqueous layers were separated and the organic layer containing the product was washed with water (110 mL).
  • Nljsrl2-diCbz-N4-spermine cholesteryl carbamate (8.5g, 9.67 mmol) was dissolved in 200 mL of acetic acid and 1.66 g of 10% Pd on carbon was added. The solution was purged with nitrogen and stirred under hydrogen at atmospheric pressure. The hydrogen was supplied to the reaction flask using a balloon filled with hydrogen gas. The hydrogenolysis was allowed to proceed for 3 hours. The reaction mixture was filtered through Whatman #1 filter paper and the catalyst was washed with 250 mL of 10% acetic acid in ethyl acetate.
  • the column was packed in 40:25 MeOH : CHCI3 and eluted with 40:25 MeOH : CHCI3 and then 40:25:10 MeOH : CHCI3 : NH4OH.
  • the fractions collected were analyzed by thin layer chromatography and the product containing fractions were combined and concentrated in vacuo (the evaporation was assisted by the addition of iso-propanol in order to azeotrope the residual water).
  • the material was vacuum dried at ambient temperature for 48 hours to give N ⁇ -spermine cholesteryl carbamate (4g, 6.5 mmol, 67% yield).
  • N-L(N'-cholesteryl carbamate glycineamideV-spermine (amphiphile No. 91) N-t-BOC-glycine-N-hydroxysuccinimide ester (0.5 g, 1.83 mmol) was added to a solution of diCbz-spermine »2HC1 (1.0 g, 1.94 mmol) and N,N- diisopropylethylamine (0.3 mL, 1.72 mmol) in 65/ 25/ 4 chloroform/ methanol/ water (50 mL). The solution was stirred overnight at room temperature. Analysis of the reaction by TLC (20% methanol/ chloroform) indicated the presence of a new spot.
  • Benzyl chloroformate (100 mg, 0.58 mmol) was added to a solution of N ,N 1 ⁇ diC ⁇ z-N ⁇ (N'-t-BOC-glycmea ⁇ de)-spe ⁇ nine (220 mg, 0.354 mmol) and triethylamine (4 drops) in methylene chloride (20 mL). The reaction was stirred overnight at room temperature. Analysis of the reaction by TLC (20% methanol/ chloroform) indicated the presence of a new, higher running spot. The reaction was quenched by the addition of IM HCl (5 mL). The organic layer was isolated, washed with H2O (5 mL), dried over sodium sulfate, filtered, and reduced in vacuo .
  • N 1 J 9 / N 12 -triCbz-N 4 -glycineamide-spermine (219 mg, 0.33 mmol) and triethylamine (0.3 mL, 2.15 mmol) in methylene chloride (30 mL).
  • the reaction was stirred at room temperature for 3 hours.
  • the reaction was washed with H2O (10 mL).
  • the organic layer was separated, dried over sodium sulfate, filtered, and reduced in vacuo .
  • the crude material was purified by flash column chromatography (30 g silica gel) eluting with 65% ethyl acetate/ hexanes.
  • 2,3 Dimyristoylglycerol (600 mg, 1.4 mmol) was dissolved in pyridine and the solution cooled to 0°C. The solution was stirred under a nitrogen atmosphere and p-toluenesulfonyl chloride (300 mg, 1.57 mmol) was added. The solution was allowed to warm to room temperature and was then stirred overnight at ambient temperature. To the solution was added hydrochloric acid (2.5M, 20 mL) and the solution was extracted three times with methylene chloride (25 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to give a crude oil.
  • p-toluenesulfonyl chloride 300 mg, 1.57 mmol
  • the oil was purified by flash chromatography (50g of silica gel, 6 ⁇ A) eluting with 5% ethyl acetate / hexane.
  • the oil obtained by flash chromatography was dried under high vacuum at ambient temperature to give 2,3-Dimyristoylglycerol-tosylate(630 mg, 77% yield).
  • N4-(Nl ⁇ « J 8 )-diCbz-s ⁇ ermidine-2,3-dilauryloxypropylamine (142 mg, 0.18 mmol) in glacial acetic acid (5 mL) was stirred with 10% Pd/C (50 mg) under a hydrogen atmosphere, for 2 hours.
  • the catalyst was removed by vacuum filtration through Whatman #1 filter paper. The catalyst was washed with ethyl / acetate hexane (10%, 10 mL). The filtrate was concentrated in vacuo and dried for 2 hours under high vacuum. To the residue was added sodium hydroxide solution (1 M, 8 mL) and the solution was extracted three times with methanol / chloroform (10%, 20 mL).
  • N ⁇ (Nl jl2-diCbz-spermme)-2,3-dilauryloxypropylmine (180 mg, 0.2 mmol) in glacial acetic acid (10 mL) was stirred with 10% Pd/C (50 mg) under a hydrogen atmosphere, for 3 hours.
  • the catalyst was removed by vacuum filtration through Whatman #1 filter paper. The catalyst was washed with ethyl / acetate hexane (10%, 30 mL). The filtrate was concentrated in vacuo and dried for 2 hours under high vacuum. To the residue was added methanol / chloroform (10%, 85 mL) and the organic layer was washed twice with sodium hydroxide solution (1 M, 15 mL) and water (10 mL). The organic fraction was dried over sodium sulfate, filtered and concentrated in vacuo to give after drying under high vacuum N4-spermine-2,3-dilauryloxypropylamine (50 mg, 40% yield).
  • Example 11- Expression of a Secreted Protein from Vascular Tissue Human secreted alkaline phosphatase (SEAP) was detected in the serum of BALB/c mice following intravenous administration of a plasmid containing an encdoing cDNA.
  • SEAP vascular Tissue Human secreted alkaline phosphatase
  • a cationic amphiphile plasmid composition was prepared.
  • a cDNA encoding sequence for human SEAP was placed in pCFl plasmid (see Example 4).
  • the transfecting composition was prepared to contain 0.75 mM of amphiphile No. 67, 1.5 mM DOPE, and 2mM (as nucleotide) of pCFl plasmid.
  • the amphiphile /DNA ratio was 1:4 thereby providing a negative zeta potential.
  • amphiphile/DNA complex As demonstrated in Figure 22, substantial expression of SEAP protein was detected in the serum of BALB/c mice following tail vein administration of the amphiphile/DNA complex.
  • pCFl plasmid with the encoding cDNA was used as control and error bars are shown. Similar results were achieved using amphiphile No. 53 (see Example 3 for preferred procedures).
  • the amphiphile/DNA complex was provided as 0.5 mM of amphiphile No. 53, 0.5 mM DOPE, and 2mM (as nucleotide) of pCFl plasmid.
  • the human retinoblastoma protein, pRB has been extensively studied along with its involvement in the control of the cell cycle (see, for example,
  • RB gene retinoblastoma tumor suppressor gene
  • mice involved use of female Beige/SCID mice, and a transfecting composition of plasmid pCTM-Rb carrying the retinoblastoma tumor suppressor gene (from Canji Corporation, see Figure 23), and amphiphile 67.
  • Intravenous (tail vein) administration of the CAT reporter gene had also been determined to result in gene transfer to both tumor and normal tissue, and could be detected in lung, heart, kidney, liver, and adrenal cells, and ovarian tumor cells.
  • mice 5 x 10 ⁇ NLH-H69 cells were injected (tail vein) using a study group of 50 mice.
  • the mice were divided into 5 groups: RB gene/lipid complex at high dose (150 ⁇ g DNA/injection); RB gene/lipid complex at low dose (75 ⁇ g DNA/injection); CAT gene/lipid complex at 150 ⁇ g DNA/injection; a PBS control; and an untreated (except for NLH-H69 cells) control.
  • Tumors were permitted to establish for three days, and on day 4 test samples were administered as as a single intravenous adminstration in a 200 ⁇ l volume (provided as 150 ⁇ g DNA, using a 1 : 1 : 4 molar ratio of amphiphile No.
  • Figure 24 demonstrates the substantial survival enhancement associated with pRB expression.
  • the lesser survival enhancement associated with reporter gene expression may reflect triggering of residual immune system defenses associated with the inflammatory response to the reporter gene /lipid complex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur de nouveaux amphiphiles cationiques favorisant le transport de molécules à activité biologique (thérapeutique), et contenant des groupes lipophiles dérivés de stéroïdes, de mono ou dialkxlamines, ou de groupes alkyle ou acyle, et des groupes cationiques susceptibles de protonation pour un pH physiologique, et dérivant d'amines, d'alkylamines ou de polyalkylamines. L'invention porte également sur des compositions thérapeutiques normalement préparées par mise en contact d'une dispersion d'un ou plusieurs amphiphiles cationiques avec des molécules thérapeutiques. Lesdites molécules, transférables dans des cellules selon les procédés de l'invention, comportent de l'ADN, de l'ARN et des polypeptides. Parmi les exemples d'utilisation des compositions thérapeutiques de l'invention figurent les thérapies géniques ou le transfert dans des cellules de polynucléotides antisens ou de polypeptides à activité biologique. En ce qui concerne les compositions thérapeutiques pour thérapies géniques, l'ADN est normalement fourni sous la forme d'un plasmide formant un complexe avec un amphiphile cationique. L'invention porte également sur de nouveaux produits d'assemblage de plasmides à haute efficacité dont ceux particulièrement efficaces pour servir à des thérapies géniques en cas d'états cliniques compliqués d'inflammation. Elle porte en outre sur le ciblage d'organes à des fins de thérapie génique par administration intraveineuse de compositions thérapeutiques.
PCT/US1997/012109 1997-07-11 1997-07-11 Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique WO1999002190A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1997/012109 WO1999002190A1 (fr) 1997-07-11 1997-07-11 Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique
AU36594/97A AU3659497A (en) 1997-07-11 1997-07-11 Organ-specific targeting of cationic amphiphile/retinobl astoma encoding dna complexes for gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/012109 WO1999002190A1 (fr) 1997-07-11 1997-07-11 Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique

Publications (1)

Publication Number Publication Date
WO1999002190A1 true WO1999002190A1 (fr) 1999-01-21

Family

ID=22261245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012109 WO1999002190A1 (fr) 1997-07-11 1997-07-11 Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique

Country Status (2)

Country Link
AU (1) AU3659497A (fr)
WO (1) WO1999002190A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047499A2 (fr) 2001-12-04 2003-06-12 Ben Gurion University Of The Negev Research And Development Authority Composes amphiphiliques et vesicules/liposomes pour le ciblage de medicaments propre a un organe
US6716882B2 (en) 1993-12-20 2004-04-06 Invitrogen Corporation Highly packed polycationic ammonium, sulfonium and phosphonium lipids
WO2004110980A1 (fr) * 2003-06-18 2004-12-23 Biolab Ltd. Conjugues de polyalkylamines de sphingolipides
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US7145039B2 (en) 1998-11-12 2006-12-05 Invitrogen Corp. Transfection reagents
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
EP2681327A4 (fr) * 2011-03-04 2015-06-03 Intrexon Corp Vecteurs exprimant une protéine de façon conditionnelle
CN105111089A (zh) * 2015-09-07 2015-12-02 南京华威医药科技开发有限公司 吡沙洛姆中间体
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021115A1 (fr) * 1993-03-25 1994-09-29 Baylor College Of Medicine Genes suppresseurs de tumeur a large spectre, produits geniques et methodes de therapie genique de suppression de tumeur
WO1996018372A2 (fr) * 1994-12-09 1996-06-20 Genzyme Corporation Amphiphiles cationiques et plasmides destines a la liberation intracellulaire de molecules therapeutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021115A1 (fr) * 1993-03-25 1994-09-29 Baylor College Of Medicine Genes suppresseurs de tumeur a large spectre, produits geniques et methodes de therapie genique de suppression de tumeur
WO1996018372A2 (fr) * 1994-12-09 1996-06-20 Genzyme Corporation Amphiphiles cationiques et plasmides destines a la liberation intracellulaire de molecules therapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEINBERG: "THE RETINOBLASTOMA PROTEIN AND CELL CYCLE CONTROL", CELL, vol. 81, 1995, pages 323 - 330, XP002058256 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716882B2 (en) 1993-12-20 2004-04-06 Invitrogen Corporation Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US7501542B2 (en) 1993-12-20 2009-03-10 Invitrogen Corporation Highly-packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US7687070B2 (en) 1994-02-11 2010-03-30 Life Technologies Corporation Reagents for intracellular delivery of macromolecules
US7145039B2 (en) 1998-11-12 2006-12-05 Invitrogen Corp. Transfection reagents
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US7166745B1 (en) 1998-11-12 2007-01-23 Invitrogen Corporation Transfection reagents
US7173154B2 (en) 1998-11-12 2007-02-06 Invitrogen Corp. Transfection reagents
US7323594B2 (en) 1998-11-12 2008-01-29 Invitrogen Corporation Transfection reagents
US7470817B2 (en) 1998-11-12 2008-12-30 Invitrogen Corporation Transfection reagents
US7479573B2 (en) 1998-11-12 2009-01-20 Invitrogen Corporation Transfection reagents
WO2003047499A2 (fr) 2001-12-04 2003-06-12 Ben Gurion University Of The Negev Research And Development Authority Composes amphiphiliques et vesicules/liposomes pour le ciblage de medicaments propre a un organe
JP2006527763A (ja) * 2003-06-18 2006-12-07 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム スフィンゴ脂質のポリアルキルアミン抱合体
US8673285B2 (en) 2003-06-18 2014-03-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Sphingoid polyalkylamine conjugates for vaccination
AU2004246904B2 (en) * 2003-06-18 2010-02-04 Biolab Ltd. Sphingolipids polyalkylamine conjugates for use in transfection
WO2004110499A1 (fr) * 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conjugues sphingolipides-polyalkylamines pouvant etre utilises dans une transfection
US7771711B2 (en) 2003-06-18 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids' polyalkylamines conjugates
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8242089B2 (en) 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
WO2004110496A1 (fr) * 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conjugues sphingoide-polyalkylamine pour la preparation d'un vaccin
WO2004110980A1 (fr) * 2003-06-18 2004-12-23 Biolab Ltd. Conjugues de polyalkylamines de sphingolipides
EP2681327A4 (fr) * 2011-03-04 2015-06-03 Intrexon Corp Vecteurs exprimant une protéine de façon conditionnelle
EP3450568A3 (fr) * 2011-03-04 2019-04-24 Intrexon Corporation Vecteurs exprimant une protéine de manière conditionnelle
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10792362B2 (en) 2014-07-15 2020-10-06 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US11872285B2 (en) 2014-07-15 2024-01-16 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CN105111089A (zh) * 2015-09-07 2015-12-02 南京华威医药科技开发有限公司 吡沙洛姆中间体

Also Published As

Publication number Publication date
AU3659497A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
AU738083B2 (en) Cationic amphiphile/ DNA complexes
EP0799059B1 (fr) Amphiphiles cationiques et plasmides destines a la liberation intracellulaire de molecules therapeutiques
US5783565A (en) Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US5767099A (en) Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5719131A (en) Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
WO1998002190A9 (fr) Complexes adn/amphiphiles cationiques
US5935936A (en) Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
AU731503B2 (en) Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6383814B1 (en) Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5747471A (en) Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
WO1998050418A1 (fr) Amphiphiles cationiques contenant des lieurs obtenus a partir d'acides amines neutres ou charges positivement
US5942634A (en) Cationic amphiphiles for cell transfections
US5910487A (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5912239A (en) Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1999002190A1 (fr) Ciblage specifique d'organes par des amphiphiles cationiques/retinoblastomes codant pour des complexes d'adn a des fins de therapie genique
US6331524B1 (en) Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
CA2268945A1 (fr) Compositions amphiphiles cationiques destinees a un apport intracellulaire de molecules therapeutiques
US20020013282A1 (en) Cationic amphipile compositions for interacelluar delivery of therapeutic molecules
WO1998050416A1 (fr) Amphiphiles cationiques a groupes lipophiles steroides multiples
AU716706C (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
AU736143B2 (en) Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
AU734980B2 (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
CA2205968A1 (fr) Amphiphiles cationiques et plasmides destines a la liberation intracellulaire de molecules therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载